CI
ABBV icon

Corient IA’s AbbVie ABBV Stock Holding History

Corient IA’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$843K Sell
3,877
-490
-11% -$109K 0.79% 21
2025
Q4 		$998K Hold
4,367
– – 0.94% 20
2025
Q3 		$1.01M Hold
4,367
– – 0.76% 28
2025
Q2 		$811K Hold
4,367
– – 0.48% 50
2025
Q1 		$915K Buy
+4,367
New +$849K 0.65% 23

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Corient IA's ABBV Position: Q1 2026 in Review

Corient IA reduced its AbbVie (ABBV) stake by 11% in Q1 2026, selling an estimated $109K and leaving 3,877 shares worth $843K. The position accounts for 0.79% of the portfolio, ranked #21.

Corient IA first reported a position in ABBV in Q1 2025 and has held it in 5 quarters since. The position peaked at $1.01M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Corient IA held 3,877 shares of AbbVie worth $843K as of Q1 2026.
  • Corient IA sold 490 AbbVie shares in Q1 2026, an estimated $109K.
  • AbbVie made up 0.79% of Corient IA's portfolio in Q1 2026, its #21 holding.
  • Corient IA first reported a position in AbbVie in Q1 2025 and has held it in 5 quarters since.
  • Corient IA's AbbVie position peaked at $1.01M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Corient IA's 13F filing for Q1 2026, filed 14 May 2026.